Valganciclovir: Does Extending Treatment Reduce Risk for CMV in Kidney Transplant Patients?

Ron Shapiro, MD


July 28, 2010

This feature requires the newest version of Flash. You can download it here.

Citation: Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant. 2010;10:1228-1237. Available at: